Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2011

View Archived Issues

Heroin-like immunoconjugate protects against addiction

Privigen shows promise to treat Alzheimer's disease in preclinical test

Confirmatory phase III trial to assess Gammagard Liquid in mild to moderate Alzheimer's disease

New biomarker to differentiate benign and dangerous pancreatic cyst neoplasms

New histamine H3 receptor antagonists prepared at Takeda

Merck KGaA presents novel sphingosine kinase 1 inhibitors

Poxel discloses new AMPK activators

Novel c-Akt inhibitors synthesized at ArQule

New GLP-1 analogues and derivatives disclosed by Novo Nordisk

Bristol-Myers Squibb synthesizes novel HCV NS5A inhibitors

New therapeutic strategy identified for inflammation and autoimmune conditions

Kowa begins phase III trial of K-115 in Japan

Molecular Response and SuperGen enter translational oncology agreement

Lupin and Medicis enter agreement for formulating multiple therapeutics

Merck & Co. submits MAA for ridaforolimus in Europe

Vanda and Biotoscana Farma enter license agreement for Fanapt in Argentina

FDA places clinical hold on phase III trials of Insmed amikacin product

Teva and Active Biotech report initial results from BRAVO trial of laquinimod

Phase IIb trial of ponesimod in MS meets primary endpoint

MM-398 receives orphan drug status in pancreatic cancer

Enrollment initiated in phase II/III study of CF-101

Enrollment begins in phase III Kiobrina trial in preterm infants

Cubist Pharmaceuticals commences pivotal phase III trial of CXA-201

NYU Langone Medical Center receives grant to conduct comparative trial in coronary artery disease

NICE issues final guidance on recommendation of Ozurdex for macular edema due to RVO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...